Analysis of Edg-Like LPA receptor-ligand interactions

Balazs Balogh, Tamas Pazmany, P. Mátyus

Research output: Contribution to journalArticle

Abstract

The phospholipid derivative lysophosphatidic acid (LPA) serves as a signalling molecule through the activation of LPA receptors, which belong to the G-protein-coupled receptors. From a pharmacological point of view, the (‘EDG-like’) LPA1-3 receptors have attracted much attention, therefore we have also been focusing in our study on these subtypes. The LPA1receptors are widely expressed in the human body; interestingly, LPA1 might have a role in the pathomechanism of obesity. In order to recognize key structural features of the molecular interactions of human LPA1with its agonists, we built up the 3D structure of the LPA1 through homology modeling. Next, LPA1 agonists and antagonists were docked into the model. The mode of binding and the interactions between ligands and key amino acids (R3.28 and Q3.29) were consistent with mutagenesis assays and previously published models, indicating that this model is able to discriminate high-affinity compounds and may be useful for the development of novel agonists of LPA1. Homology models were also constructed for LPA2 and LPA3. All available agonists with published EC50 values, antagonists with IC50 values and compounds with Ki values for either of LPA1, LPA2 or LPA3 were collected from the ChEMBL database and were docked into the corresponding model.Ourmodels for the LPA1-3 receptors can discriminate high-affinity compounds identified in silico HTS studies and may be useful for the development of novel agonistsof LPA receptors. With a better understanding of the differences between LPA1-3 receptors new, selective agonists and antagonist could be designed, which could be used in the therapy of various diseases with a better side-effect profile.

Original languageEnglish
Pages (from-to)3533-3547
Number of pages15
JournalCurrent Pharmaceutical Design
Volume21
Issue number24
Publication statusPublished - Aug 1 2015

Fingerprint

Lysophosphatidic Acid Receptors
Ligands
G-Protein-Coupled Receptors
Human Body
Mutagenesis
Computer Simulation
Inhibitory Concentration 50
Phospholipids
Obesity
Databases
Pharmacology
Amino Acids

Keywords

  • Docking
  • Lpa agonist
  • Lpa antagonist
  • Lysophosphatidic acid
  • Lysophospholipid

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Analysis of Edg-Like LPA receptor-ligand interactions. / Balogh, Balazs; Pazmany, Tamas; Mátyus, P.

In: Current Pharmaceutical Design, Vol. 21, No. 24, 01.08.2015, p. 3533-3547.

Research output: Contribution to journalArticle

Balogh, B, Pazmany, T & Mátyus, P 2015, 'Analysis of Edg-Like LPA receptor-ligand interactions', Current Pharmaceutical Design, vol. 21, no. 24, pp. 3533-3547.
Balogh, Balazs ; Pazmany, Tamas ; Mátyus, P. / Analysis of Edg-Like LPA receptor-ligand interactions. In: Current Pharmaceutical Design. 2015 ; Vol. 21, No. 24. pp. 3533-3547.
@article{2a210f73399a4b7c9f687d6c6d2bcd12,
title = "Analysis of Edg-Like LPA receptor-ligand interactions",
abstract = "The phospholipid derivative lysophosphatidic acid (LPA) serves as a signalling molecule through the activation of LPA receptors, which belong to the G-protein-coupled receptors. From a pharmacological point of view, the (‘EDG-like’) LPA1-3 receptors have attracted much attention, therefore we have also been focusing in our study on these subtypes. The LPA1receptors are widely expressed in the human body; interestingly, LPA1 might have a role in the pathomechanism of obesity. In order to recognize key structural features of the molecular interactions of human LPA1with its agonists, we built up the 3D structure of the LPA1 through homology modeling. Next, LPA1 agonists and antagonists were docked into the model. The mode of binding and the interactions between ligands and key amino acids (R3.28 and Q3.29) were consistent with mutagenesis assays and previously published models, indicating that this model is able to discriminate high-affinity compounds and may be useful for the development of novel agonists of LPA1. Homology models were also constructed for LPA2 and LPA3. All available agonists with published EC50 values, antagonists with IC50 values and compounds with Ki values for either of LPA1, LPA2 or LPA3 were collected from the ChEMBL database and were docked into the corresponding model.Ourmodels for the LPA1-3 receptors can discriminate high-affinity compounds identified in silico HTS studies and may be useful for the development of novel agonistsof LPA receptors. With a better understanding of the differences between LPA1-3 receptors new, selective agonists and antagonist could be designed, which could be used in the therapy of various diseases with a better side-effect profile.",
keywords = "Docking, Lpa agonist, Lpa antagonist, Lysophosphatidic acid, Lysophospholipid",
author = "Balazs Balogh and Tamas Pazmany and P. M{\'a}tyus",
year = "2015",
month = "8",
day = "1",
language = "English",
volume = "21",
pages = "3533--3547",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "24",

}

TY - JOUR

T1 - Analysis of Edg-Like LPA receptor-ligand interactions

AU - Balogh, Balazs

AU - Pazmany, Tamas

AU - Mátyus, P.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The phospholipid derivative lysophosphatidic acid (LPA) serves as a signalling molecule through the activation of LPA receptors, which belong to the G-protein-coupled receptors. From a pharmacological point of view, the (‘EDG-like’) LPA1-3 receptors have attracted much attention, therefore we have also been focusing in our study on these subtypes. The LPA1receptors are widely expressed in the human body; interestingly, LPA1 might have a role in the pathomechanism of obesity. In order to recognize key structural features of the molecular interactions of human LPA1with its agonists, we built up the 3D structure of the LPA1 through homology modeling. Next, LPA1 agonists and antagonists were docked into the model. The mode of binding and the interactions between ligands and key amino acids (R3.28 and Q3.29) were consistent with mutagenesis assays and previously published models, indicating that this model is able to discriminate high-affinity compounds and may be useful for the development of novel agonists of LPA1. Homology models were also constructed for LPA2 and LPA3. All available agonists with published EC50 values, antagonists with IC50 values and compounds with Ki values for either of LPA1, LPA2 or LPA3 were collected from the ChEMBL database and were docked into the corresponding model.Ourmodels for the LPA1-3 receptors can discriminate high-affinity compounds identified in silico HTS studies and may be useful for the development of novel agonistsof LPA receptors. With a better understanding of the differences between LPA1-3 receptors new, selective agonists and antagonist could be designed, which could be used in the therapy of various diseases with a better side-effect profile.

AB - The phospholipid derivative lysophosphatidic acid (LPA) serves as a signalling molecule through the activation of LPA receptors, which belong to the G-protein-coupled receptors. From a pharmacological point of view, the (‘EDG-like’) LPA1-3 receptors have attracted much attention, therefore we have also been focusing in our study on these subtypes. The LPA1receptors are widely expressed in the human body; interestingly, LPA1 might have a role in the pathomechanism of obesity. In order to recognize key structural features of the molecular interactions of human LPA1with its agonists, we built up the 3D structure of the LPA1 through homology modeling. Next, LPA1 agonists and antagonists were docked into the model. The mode of binding and the interactions between ligands and key amino acids (R3.28 and Q3.29) were consistent with mutagenesis assays and previously published models, indicating that this model is able to discriminate high-affinity compounds and may be useful for the development of novel agonists of LPA1. Homology models were also constructed for LPA2 and LPA3. All available agonists with published EC50 values, antagonists with IC50 values and compounds with Ki values for either of LPA1, LPA2 or LPA3 were collected from the ChEMBL database and were docked into the corresponding model.Ourmodels for the LPA1-3 receptors can discriminate high-affinity compounds identified in silico HTS studies and may be useful for the development of novel agonistsof LPA receptors. With a better understanding of the differences between LPA1-3 receptors new, selective agonists and antagonist could be designed, which could be used in the therapy of various diseases with a better side-effect profile.

KW - Docking

KW - Lpa agonist

KW - Lpa antagonist

KW - Lysophosphatidic acid

KW - Lysophospholipid

UR - http://www.scopus.com/inward/record.url?scp=84939864402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939864402&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 3533

EP - 3547

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 24

ER -